Included in the formulation
АТХ:C.01.E.B Other drugs for the treatment of heart disease
Pharmacodynamics:Suppression of automatism sinoarthriasis and Purkinje fibers (blockade of Ca2+channels and an increase in permeability for K+). Improves metabolism and energy supply of tissues.
Pharmacokinetics:After parenteral administration, it penetrates into the cells of the organs, where it is split into adenosine and inorganic phosphate with energy release.
Indications:Muscular dystrophy and atony, poliomyelitis, multiple sclerosis; pigmentary degeneration of the retina; diseases of peripheral vessels (intermittent claudication, Raynaud's disease, thromboangiitis obliterans); suppression of paroxysms of supraventricular tachycardia, ischemic heart disease; weakness of labor.
I.A80-A89.A80 Acute poliomyelitis
VI.G35-G37.G35 Multiple sclerosis
VI.G70-G73.G71.0 Muscular dystrophy
VII.H30-H36.H31.1 Degeneration of the choroid
IX.I20-I25.I20 Angina pectoris [angina pectoris]
IX.I30-I52.I47.1 Nadzheludochkovaya tachycardia
IX.I70-I79.I73.0 Raynaud's syndrome
IX.I70-I79.I73.1 Obliterating thromboangitis [Berger's disease]
IX.I70-I79.I73.9 Peripheral vascular disease, unspecified
XV.O60-O75.O62 Violations of labor [of the clan]
Contraindications:Hypersensitivity, acute myocardial infarction, arterial hypotension, inflammatory lung diseases.
Carefully:Joint reception of cardiac glycosides.
Pregnancy and lactation:Adequate and well-controlled studies in humans and animals have not been conducted. There is no information on the penetration into breast milk.
Category of recommendations for FDA is not defined.
Dosing and Administration:With supraventricular paroxysmal tachycardia: intramuscular, intravenous or intra-arterial. In the first days of treatment - intramuscularly 10 mg (1 ml of 1% solution) once a day, then in the same dose 2 times a day or 20 mg once a day. The course of treatment is 30-40 injections, a second course in 1-2 months.For arresting supraventricular arrhythmias: intravenously 10-20 mg for 5-6 seconds, re-introduction after 2-3 min.
Side effects:With intramuscular injection: headache, tachycardia, an increase in diuresis, hyperuricemia are possible.
With intravenous administration: nausea, hyperemia of the facial skin, headache, weakness are possible.
Allergic reactions: rarely - itching, skin hyperemia.
Overdose:Not described.
Treatment is symptomatic.
Interaction:Cardiac glycosides - increase the risk of side effects (including increase the arrhythmogenic effect).
Special instructions:In comparison with verapamil it quickly restores the normal rhythm in the treatment of supraventricular paroxysmal tachycardia, however, trifosadenin has more side effects (ventricular ectopies and a general feeling of discomfort).
Compared with adenosine phosphate (6.6 mg trifosadenina equivalent 3.8 mg adenosine phosphate) is also effective and safe in the treatment of paroxysmal supraventricular tachycardia, however adenosine phosphate gives a more stable effect.